{"title":"印度阿育吠陀医学:概述及在脑癌中的应用","authors":"Herbert B. Newton","doi":"10.1016/j.jaim.2024.101013","DOIUrl":null,"url":null,"abstract":"<div><p>Ayurveda is the traditional medicine system of India, and has been in practice for millennia. It is a traditional approach that uses 1000's of different plant preparations in various combinations for treatment of human ailments, including cancer. Ethnopharmacological and phytochemical analyses are now elucidating the bioactive constituents of the different plant species and herbal formulations, including ashwagandha, curcumin, guduchi, triphala, and others.</p><p>To provide an overview of: 1) the ethnopharmacology of Ayurveda and several of its most important plant species and formulations, including pharmacological and molecular mechanisms of its anti-cancer effects; 2) review the literature applying Ayurvedic herbs and formulations to brain tumors.</p><p>A detailed PubMed search was performed that included publications involving Ayurveda, cancer, ethnopharmacology, phytochemical analysis, molecular analysis, and brain tumors.</p><p>In recent decades, significant research has begun to elucidate the bioactive compounds of ashwagandha, tumeric, guduchi, and triphala, such as withaferin A, withanolides, curcumin, palmatine, and many others. These compounds and extracts are now being applied to brain tumor cells <em>in vitro</em> and in animal models, with positive signs of anti-cancer activity including reduced cell growth, increased apoptosis, cell cycle arrest, increased differentiation, and inhibition of important internal signal transduction pathways.</p><p>Several Ayurvedic herbs (ashwagandha, curcumin) have bioactive compounds with significant anti-cancer activity, and are effective in early pre-clinical testing against brain tumor cells <em>in vitro</em> and in animal models. Further pre-clinical testing is warranted, along with advancement into phase I and phase II clinical trials of patients with glioblastoma and other brain tumors.</p></div>","PeriodicalId":15150,"journal":{"name":"Journal of Ayurveda and Integrative Medicine","volume":"15 4","pages":"Article 101013"},"PeriodicalIF":1.7000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0975947624001281/pdfft?md5=03d9a8aedfb3f5972e5386f43fd69bbf&pid=1-s2.0-S0975947624001281-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Indian Ayurvedic medicine: Overview and application to brain cancer\",\"authors\":\"Herbert B. Newton\",\"doi\":\"10.1016/j.jaim.2024.101013\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Ayurveda is the traditional medicine system of India, and has been in practice for millennia. It is a traditional approach that uses 1000's of different plant preparations in various combinations for treatment of human ailments, including cancer. Ethnopharmacological and phytochemical analyses are now elucidating the bioactive constituents of the different plant species and herbal formulations, including ashwagandha, curcumin, guduchi, triphala, and others.</p><p>To provide an overview of: 1) the ethnopharmacology of Ayurveda and several of its most important plant species and formulations, including pharmacological and molecular mechanisms of its anti-cancer effects; 2) review the literature applying Ayurvedic herbs and formulations to brain tumors.</p><p>A detailed PubMed search was performed that included publications involving Ayurveda, cancer, ethnopharmacology, phytochemical analysis, molecular analysis, and brain tumors.</p><p>In recent decades, significant research has begun to elucidate the bioactive compounds of ashwagandha, tumeric, guduchi, and triphala, such as withaferin A, withanolides, curcumin, palmatine, and many others. These compounds and extracts are now being applied to brain tumor cells <em>in vitro</em> and in animal models, with positive signs of anti-cancer activity including reduced cell growth, increased apoptosis, cell cycle arrest, increased differentiation, and inhibition of important internal signal transduction pathways.</p><p>Several Ayurvedic herbs (ashwagandha, curcumin) have bioactive compounds with significant anti-cancer activity, and are effective in early pre-clinical testing against brain tumor cells <em>in vitro</em> and in animal models. Further pre-clinical testing is warranted, along with advancement into phase I and phase II clinical trials of patients with glioblastoma and other brain tumors.</p></div>\",\"PeriodicalId\":15150,\"journal\":{\"name\":\"Journal of Ayurveda and Integrative Medicine\",\"volume\":\"15 4\",\"pages\":\"Article 101013\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S0975947624001281/pdfft?md5=03d9a8aedfb3f5972e5386f43fd69bbf&pid=1-s2.0-S0975947624001281-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Ayurveda and Integrative Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0975947624001281\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INTEGRATIVE & COMPLEMENTARY MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Ayurveda and Integrative Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0975947624001281","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INTEGRATIVE & COMPLEMENTARY MEDICINE","Score":null,"Total":0}
引用次数: 0
摘要
阿育吠陀是印度的传统医学体系,已有千年历史。阿育吠陀是印度的传统医学体系,已有数千年的历史。它采用传统方法,将 1000 多种不同的植物制剂进行各种组合,用于治疗包括癌症在内的人类疾病。目前,民族药理学和植物化学分析正在阐明不同植物物种和草药配方的生物活性成分,包括灰树叶、姜黄素、古杜奇、三叶草等:1) 阿育吠陀的民族药理学及其几种最重要的植物品种和配方,包括其抗癌作用的药理学和分子机制;2) 综述将阿育吠陀草药和配方应用于脑肿瘤的文献。我们在 PubMed 上进行了详细搜索,包括涉及阿育吠陀、癌症、民族药理学、植物化学分析、分子分析和脑肿瘤的出版物。近几十年来,大量研究已开始阐明灰树叶、吐根、古杜奇和三叶草的生物活性化合物,如含铁血黄素 A、黄烷醇内酯、姜黄素、巴马汀等。目前,这些化合物和提取物正被用于体外和动物模型中的脑肿瘤细胞,并出现了抗癌活性的积极迹象,包括减少细胞生长、增加细胞凋亡、细胞周期停滞、增加分化和抑制重要的内部信号转导途径。一些阿育吠陀草药(灰树花、姜黄素)中的生物活性化合物具有显著的抗癌活性,在早期临床前试验中对体外和动物模型中的脑肿瘤细胞有效。有必要进一步进行临床前试验,并推进对胶质母细胞瘤和其他脑肿瘤患者的 I 期和 II 期临床试验。
Indian Ayurvedic medicine: Overview and application to brain cancer
Ayurveda is the traditional medicine system of India, and has been in practice for millennia. It is a traditional approach that uses 1000's of different plant preparations in various combinations for treatment of human ailments, including cancer. Ethnopharmacological and phytochemical analyses are now elucidating the bioactive constituents of the different plant species and herbal formulations, including ashwagandha, curcumin, guduchi, triphala, and others.
To provide an overview of: 1) the ethnopharmacology of Ayurveda and several of its most important plant species and formulations, including pharmacological and molecular mechanisms of its anti-cancer effects; 2) review the literature applying Ayurvedic herbs and formulations to brain tumors.
A detailed PubMed search was performed that included publications involving Ayurveda, cancer, ethnopharmacology, phytochemical analysis, molecular analysis, and brain tumors.
In recent decades, significant research has begun to elucidate the bioactive compounds of ashwagandha, tumeric, guduchi, and triphala, such as withaferin A, withanolides, curcumin, palmatine, and many others. These compounds and extracts are now being applied to brain tumor cells in vitro and in animal models, with positive signs of anti-cancer activity including reduced cell growth, increased apoptosis, cell cycle arrest, increased differentiation, and inhibition of important internal signal transduction pathways.
Several Ayurvedic herbs (ashwagandha, curcumin) have bioactive compounds with significant anti-cancer activity, and are effective in early pre-clinical testing against brain tumor cells in vitro and in animal models. Further pre-clinical testing is warranted, along with advancement into phase I and phase II clinical trials of patients with glioblastoma and other brain tumors.